{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T15:47:21Z","timestamp":1780069641713,"version":"3.54.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Initial treatment for prolactinoma is usually conservative with dopamine agonists. However, the duration of treatment is often lifelong and can be associated with significant side effects. Surgical outcomes are usually favorable and treatment complications low, raising the question whether surgical therapy should be included earlier in the treatment of prolactinoma. The aim of this study was to analyze the outcome of surgical resection of prolactinomas at our institution, to compare it with other published surgical and conservative series and to discuss the role of surgery in modern prolactinoma therapy. The authors reviewed a database of single-center consecutively operated prolactinoma cases and analyzed the extent of resection (EOR), endocrinological and neurological outcomes, and complications. Thirty patients were analyzed. Mean patient age was 37.2 \u00b1 15.5 years (range 16\u201376) and consisted of 17 (56.7%) females and 13 (43.3%) males. Twenty-one patients (70%) failed medical therapy, the main reasons being intolerable side effects in 11 cases (52.4%) and insufficient response in 10 cases (47.6%). Nine patients (30%) received no medical treatment prior to surgery, of which five (55.6%) were operated because of pituitary apoplexy, two (22.2%) because of acute visual deterioration and two (22.2%) refused medical treatment and opted for surgery as first-line treatment. Of the 30 operated tumors, 56.7% (<jats:italic>n<\/jats:italic> = 17) were microadenomas, 30% (<jats:italic>n<\/jats:italic> = 9) were macroadenomas (\u2265 10 mm), and 13.3% (<jats:italic>n<\/jats:italic> = 4) were giant adenomas (\u2265 40 mm). GTR was achieved in 75% (<jats:italic>n<\/jats:italic> = 21) of cases. The overall remission rate was 63.3%. MRI showed a residual tumor in seven patients (25%), typically with invasive growth. Postoperative CSF leaks did not occur. Mean follow-up was 34.9 \u00b1 60.3 months (range 0\u2013246 months). Endocrine remission was defined as a morning fasting basal PRL level of 22.3 &lt; ng\/mL and measured at the last available follow-up. Postoperative Prolactine levels were missing in three patients. Our analysis describes a highly selected sample with a disproportionate number of larger, invasive tumors and emergency cases. Nevertheless, the results are satisfactory and comparable with other published series. The consistently good results of transphenoidal surgery, especially for microprolactinomas, have led to a greater acceptance of surgery in the treatment of prolactinomas in recent years. The timing of surgery in each individual case must be determined by a multidisciplinary team to ensure the best possible outcome.<\/jats:p>","DOI":"10.1007\/s10143-023-02033-0","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T11:02:27Z","timestamp":1685444547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Surgery as first-line treatment for prolactinoma? Discussion of the literature and results of a consecutive series of surgically treated patients"],"prefix":"10.1007","volume":"46","author":[{"given":"Malte","family":"Ottenhausen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea-Marie","family":"Wolters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Ringel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"issue":"2","key":"2033_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1001\/jama.2020.3744","volume":"325","author":"PP Huynh","year":"2021","unstructured":"Huynh PP, Ishii LE, Ishii M (2021) Prolactinomas. JAMA 325(2):195. https:\/\/doi.org\/10.1001\/jama.2020.3744","journal-title":"JAMA"},{"issue":"5","key":"2033_CR2","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jama.2016.19699","volume":"317","author":"ME Molitch","year":"2017","unstructured":"Molitch ME (2017) Diagnosis and treatment of pituitary adenomas: a review. JAMA 317(5):516\u2013524. https:\/\/doi.org\/10.1001\/jama.2016.19699","journal-title":"JAMA"},{"issue":"1","key":"2033_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1227\/NEU.0000000000001740","volume":"90","author":"M Castle-Kirszbaum","year":"2022","unstructured":"Castle-Kirszbaum M, Wang YY, King J, Goldschlager T (2022) Quality of life after endoscopic surgical management of pituitary adenomas. Neurosurgery 90(1):81\u201391. https:\/\/doi.org\/10.1227\/NEU.0000000000001740","journal-title":"Neurosurgery"},{"issue":"3","key":"2033_CR4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3171\/2012.6.JNS111066","volume":"117","author":"ED McCoul","year":"2012","unstructured":"McCoul ED, Anand VK, Schwartz TH (2012) Improvements in site-specific quality of life 6 months after endoscopic anterior skull base surgery: a prospective study. J Neurosurg 117(3):498\u2013506. https:\/\/doi.org\/10.3171\/2012.6.JNS111066","journal-title":"J Neurosurg"},{"issue":"14","key":"2033_CR5","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJM199410063311403","volume":"331","author":"J Webster","year":"1994","unstructured":"Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331(14):904\u2013909. https:\/\/doi.org\/10.1056\/NEJM199410063311403","journal-title":"N Engl J Med"},{"issue":"3","key":"2033_CR6","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1210\/clinem\/dgz144","volume":"105","author":"AH Zamanipoor Najafabadi","year":"2020","unstructured":"Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, Broersen LHA, van den Akker-van Marle ME, Pereira AM, Peul WC, Dekkers OM, van Furth WR, Biermasz NR (2020) Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis. J Clin Endocrinol Metab 105(3):e32\u2013e41. https:\/\/doi.org\/10.1210\/clinem\/dgz144","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2033_CR7","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1530\/EO-21-0038","volume":"2","author":"SMC De Sousa","year":"2022","unstructured":"De Sousa SMC (2022) Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management? Endocr Oncol 2(1):R31\u2013R50. https:\/\/doi.org\/10.1530\/EO-21-0038","journal-title":"Endocr Oncol"},{"issue":"3","key":"2033_CR8","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1530\/EJE-16-0087","volume":"175","author":"M Tampourlou","year":"2016","unstructured":"Tampourlou M, Trifanescu R, Paluzzi A, Ahmed SK, Karavitaki N (2016) Therapy of endocrine disease: surgery in microprolactinomas: effectiveness and risks based on contemporary literature. Eur J Endocrinol 175(3):R89\u2013R96. https:\/\/doi.org\/10.1530\/EJE-16-0087","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2033_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11102-019-01016-z","volume":"23","author":"J Honegger","year":"2020","unstructured":"Honegger J, Nasi-Kordhishti I, Aboutaha N, Giese S (2020) Surgery for prolactinomas: a better choice? Pituitary 23(1):45\u201351. https:\/\/doi.org\/10.1007\/s11102-019-01016-z","journal-title":"Pituitary"},{"issue":"4","key":"2033_CR10","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1227\/00006123-199310000-00008","volume":"33","author":"E Knosp","year":"1993","unstructured":"Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33(4):610\u2013617. https:\/\/doi.org\/10.1227\/00006123-199310000-00008","journal-title":"Neurosurgery"},{"issue":"5","key":"2033_CR11","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1530\/EJE-11-1000","volume":"166","author":"V Primeau","year":"2012","unstructured":"Primeau V, Raftopoulos C, Maiter D (2012) Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur J Endocrinol 166(5):779\u2013786. https:\/\/doi.org\/10.1530\/EJE-11-1000","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2033_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1530\/EJE-07-0248","volume":"158","author":"J Kreutzer","year":"2008","unstructured":"Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch R, Buchfelder M (2008) Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 158(1):11\u201318. https:\/\/doi.org\/10.1530\/EJE-07-0248","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2033_CR13","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.3171\/2011.1.FOCUS10317","volume":"30","author":"CP Hofstetter","year":"2011","unstructured":"Hofstetter CP, Shin BJ, Mubita L, Huang C, Anand VK, Boockvar JA, Schwartz TH (2011) Endoscopic endonasal transsphenoidal surgery for functional pituitary adenomas. Neurosurg Focus 30(4):E10","journal-title":"Neurosurg Focus"},{"issue":"5","key":"2033_CR14","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00701-016-2762-z","volume":"158","author":"S Akin","year":"2016","unstructured":"Akin S, Isikay I, Soylemezoglu F, Yucel T, Gurlek A, Berker M (2016) Reasons and results of endoscopic surgery for prolactinomas: 142 surgical cases. Acta Neurochir (Wien) 158(5):933\u2013942. https:\/\/doi.org\/10.1007\/s00701-016-2762-z","journal-title":"Acta Neurochir (Wien)"},{"issue":"4","key":"2033_CR15","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1055\/s-0037-1615748","volume":"79","author":"F Yoo","year":"2018","unstructured":"Yoo F, Chan C, Kuan EC, Bergsneider M, Wang MB (2018) Comparison of male and female prolactinoma patients requiring surgical intervention. J Neurol Surg B Skull Base 79(4):394\u2013400. https:\/\/doi.org\/10.1055\/s-0037-1615748","journal-title":"J Neurol Surg B Skull Base"},{"issue":"1","key":"2033_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4158\/EP161446.OR","volume":"23","author":"D Donegan","year":"2017","unstructured":"Donegan D, Atkinson JL, Jentoft M, Natt N, Nippoldt TB, Erickson B, Meyer F, Erickson D (2017 Jan) Surgical outcomes of prolactinomas in recent era: results of a heterogenous group. Endocr Pract 23(1):37\u201345. https:\/\/doi.org\/10.4158\/EP161446.OR","journal-title":"Endocr Pract"},{"key":"2033_CR17","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1016\/j.wneu.2021.07.035","volume":"154","author":"K Wright","year":"2021","unstructured":"Wright K, Chaker L, Pacione D, Sam K, Feelders R, Xia Y, Agrawal N (2021) Determinants of surgical remission in prolactinomas: a systematic review and meta-analysis. World Neurosurg 154:e349\u2013e369. https:\/\/doi.org\/10.1016\/j.wneu.2021.07.035","journal-title":"World Neurosurg"},{"issue":"3","key":"2033_CR18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11102-016-0708-3","volume":"19","author":"SC Dogansen","year":"2016","unstructured":"Dogansen SC, Selcukbiricik OS, Tanrikulu S, Yarman S (2016) Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when? Pituitary 19(3):303\u2013310. https:\/\/doi.org\/10.1007\/s11102-016-0708-3","journal-title":"Pituitary"},{"issue":"1","key":"2033_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11102-010-0261-4","volume":"14","author":"M Menucci","year":"2011","unstructured":"Menucci M, Qui\u00f1ones-Hinojosa A, Burger P, Salvatori R (2011) Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary 14(1):68\u201374. https:\/\/doi.org\/10.1007\/s11102-010-0261-4","journal-title":"Pituitary"},{"issue":"10","key":"2033_CR20","doi-asserted-by":"publisher","first-page":"bvab074","DOI":"10.1210\/jendso\/bvab074","volume":"5","author":"MC Penn","year":"2021","unstructured":"Penn MC, Cardinal T, Zhang Y, Abt B, Bonney PA, Lorenzo P, Lin M, Rosner J, Weiss M, Zada G, Carmichael JD (2021) Cure and hormonal control after prolactinoma resection: case series and systematic review. J Endocr Soc 5(10):bvab074. https:\/\/doi.org\/10.1210\/jendso\/bvab074","journal-title":"J Endocr Soc"},{"issue":"1","key":"2033_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000497331","volume":"109","author":"M Buchfelder","year":"2019","unstructured":"Buchfelder M, Zhao Y, Schlaffer SM (2019) Surgery for prolactinomas to date. Neuroendocrinology 109(1):77\u201381. https:\/\/doi.org\/10.1159\/000497331","journal-title":"Neuroendocrinology"},{"key":"2033_CR22","doi-asserted-by":"publisher","first-page":"e858","DOI":"10.1016\/j.wneu.2022.12.003","volume":"170","author":"A Uzuner","year":"2023","unstructured":"Uzuner A, Yilmaz E, Caklili M, Selek A, Aydemir F, Cabuk B, Anik I, Ceylan S (2023) Endoscopic transnasal approach for microprolactinomas with experience of 105 cases in a single center: paradigmal shift for conventional medical therapy. World Neurosurg 170:e858\u2013e867. https:\/\/doi.org\/10.1016\/j.wneu.2022.12.003","journal-title":"World Neurosurg"},{"issue":"7","key":"2033_CR23","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1210\/jcem.87.7.8645","volume":"87","author":"M Losa","year":"2002","unstructured":"Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M (2002) Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab 87(7):3180\u20133186. https:\/\/doi.org\/10.1210\/jcem.87.7.8645","journal-title":"J Clin Endocrinol Metab"},{"key":"2033_CR24","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.wneu.2017.01.022","volume":"101","author":"A Li","year":"2017","unstructured":"Li A, Liu W, Cao P, Zheng Y, Bu Z, Zhou T (2017) Endoscopic versus microscopic transsphenoidal surgery in the treatment of pituitary adenoma: a systematic review and meta-analysis. World Neurosurg 101:236\u2013246. https:\/\/doi.org\/10.1016\/j.wneu.2017.01.022","journal-title":"World Neurosurg"},{"issue":"4","key":"2033_CR25","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3171\/2018.11.JNS181238","volume":"132","author":"AS Little","year":"2019","unstructured":"Little AS, Kelly DF, White WL, Gardner PA, Fernandez-Miranda JC, Chicoine MR, Barkhoudarian G, Chandler JP, Prevedello DM, Liebelt BD, Sfondouris J, Mayberg MR, TRANSSPHER Study Group (2019) Results of a prospective multicenter controlled study comparing surgical outcomes of microscopic versus fully endoscopic transsphenoidal surgery for nonfunctioning pituitary adenomas: the Transsphenoidal Extent of Resection (TRANSSPHER) Study. J Neurosurg 132(4):1043\u20131053. https:\/\/doi.org\/10.3171\/2018.11.JNS181238","journal-title":"J Neurosurg"},{"issue":"6","key":"2033_CR26","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s11102-021-01168-x","volume":"24","author":"JY Park","year":"2021","unstructured":"Park JY, Choi W, Hong AR, Yoon JH, Kim HK, Jang WY, Jung S, Kang HC (2021) Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas. Pituitary 24(6):955\u2013963. https:\/\/doi.org\/10.1007\/s11102-021-01168-x","journal-title":"Pituitary"},{"issue":"2","key":"2033_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1023\/a:1012905415868","volume":"54","author":"P Nomikos","year":"2001","unstructured":"Nomikos P, Buchfelder M, Fahlbusch R (2001) Current management of prolactinomas. J Neurooncol 54(2):139\u2013150. https:\/\/doi.org\/10.1023\/a:1012905415868","journal-title":"J Neurooncol"},{"issue":"4","key":"2033_CR28","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ejim.2008.11.012","volume":"20","author":"M Kars","year":"2009","unstructured":"Kars M, Pereira AM, Smit JW, Romijn JA (2009) Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists. Eur J Intern Med 20(4):387\u2013393. https:\/\/doi.org\/10.1016\/j.ejim.2008.11.012","journal-title":"Eur J Intern Med"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-023-02033-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-023-02033-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-023-02033-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T18:07:39Z","timestamp":1705946859000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-023-02033-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2033"],"URL":"https:\/\/doi.org\/10.1007\/s10143-023-02033-0","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"assertion":[{"value":"12 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional review board approval was obtained for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}